Summary of COVID-19 ensovibep studies

1. Kingsley et al., The Designed Ankyrin Repeat Protein Antiviral Ensovibep for Nonhospitalized Patients With Coronavirus Disease 2019: Results From EMPATHY, a Randomized, Placebo-Controlled Phase 2 Study

400 patient ensovibep early treatment RCT: 89% lower mortality (p=0.06), 78% fewer combined hospitalization/ER visits (p=0.02), 87% lower hospitalization (p=0.01), and 87% improvement (p=0.01).
RCT 407 mild to moderate COVID-19 outpatients showing faster viral clearance, lower risk of hospitalization/ER visits, and shorter time to sustained recovery with ensovibep treatment (75/225/600mg single infusion). There were 2 COVID-19 related deaths in the placebo group and none in the ensovibep groups.
May 2024, Open Forum Infectious Diseases, https://academic.oup.com/ofid/advance-article/doi/10.1093/ofid/ofae233/7664367, https://c19p.org/kingsley

2. Barkauskas et al., Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19

485 patient ensovibep late treatment RCT: 28% lower mortality (p=0.16), 11% lower combined mortality/hospitalization (p=0.47), 6% improved recovery (p=0.55), and 7% higher hospital discharge (p=0.46).
RCT 485 hospitalized patients showing no significant differences with ensovibep treatment. Intravenous ensovibep, 600mg. Long-term results are reported in [Mourad]
Aug 2022, Annals of Internal Medicine, https://www.acpjournals.org/doi/10.7326/M22-1503, https://c19p.org/barkauskas